CCRM
CCRM is a Canadian not-for-profit commercialization platform for regenerative medicine and cell and gene therapies, operating GMP manufacturing through its OmniaBio CDMO subsidiary, an academic-to-venture incubation program, and global hubs in Canada, Sweden, and Australia serving biotech, pharma, and academic clients.
- Company typePrivate
- Founded2011
- HeadquartersToronto, Canada
- Headcount101–250
- GTM typeB2B
- OfferingServices
What CCRM does
CCRM (Centre for Commercialization of Regenerative Medicine) is a Canadian not-for-profit organization founded in 2011 and headquartered at the MaRS Centre in Toronto. It operates as an integrated commercialization platform for regenerative medicine and cell and gene therapies, addressing bottlenecks that prevent academic discoveries from reaching clinical and commercial scale. The organization bundles four interlocking offerings: CGT Manufacturing services through its wholly-owned CDMO subsidiary OmniaBio Inc. (which operates a $145M, 100,000+ sq. ft. facility at McMaster Innovation Park in Hamilton with 300+ scientific staff and 10 ISO Class 7/Grade B clean rooms), a Technology Development Incubation Program that creates new ventures from academic IP (Notch Therapeutics is the flagship end-to-end incubated company), Venture Investment in portfolio companies, and the DeepTech Bio Lab launched in 2025 to apply quantum computing, AI, and robotics to advanced therapy development.
The business model combines CDMO managed services (OmniaBio), licensing and royalties from incubated ventures, professional services for advanced therapy developers, and ongoing lab contracts to portfolio companies. CCRM serves academic researchers, biotech and pharma companies, and advanced therapy developers across more than 200 institutional partners and a global hub network spanning Toronto (CCRM), Mölndal (CCRM Nordic), Melbourne (CCRM Australia), and a planned fourth hub in Ireland supported by a Government of Ireland MOU. The organization has produced 18 portfolio companies with two exits and over CA$1.2B raised by those companies to date. Strategic capital comes from the Ontario government's $580M commitment to OmniaBio and from corporate investors such as IonQ, with whom CCRM is collaborating on quantum-AI applications for bioprocess optimization.
CCRM firmographics
Firmographics- Name
- CCRM
- Legal name
- Centre for Commercialization of Regenerative Medicine
- Website
- https://ccrm.ca
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CCRM is a Canadian not-for-profit commercialization platform for regenerative medicine and cell and gene therapies, operating GMP manufacturing through its OmniaBio CDMO subsidiary, an academic-to-venture incubation program, and global hubs in Canada, Sweden, and Australia serving biotech, pharma, and academic clients.
- Ownership category
- akta.pro rank
CCRM industry classification
Industry- Product category
- Cell and Gene Therapy CDMO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
- akta.pro secondary industries
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where CCRM is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices4 records
Markets served
CCRM business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- CDMO Services (OmniaBio): Contract development and manufacturing organization services for cell and gene therapies through subsidiary OmniaBio, including GMP manufacturing, process development, and commercial-scale production
- Technology Incubation and Licensing: Internal company creation and technology licensing through incubation program, bundling IP from academic institutions and launching new ventures
- Professional Services: Consulting, commercialization support, and expertise services for advanced therapy development
- Lab Contract Services: Ongoing laboratory services provided to incubated and graduated companies
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
CCRM product offering
Product offeringCore offering
CCRM is a not-for-profit commercialization catalyst for regenerative medicine and cell/gene therapies, offering an integrated platform that bundles technology sourcing from academic labs, IP licensing, company incubation, venture investment, and GMP manufacturing services. Its wholly-owned CDMO subsidiary OmniaBio delivers commercial-scale cell and gene therapy manufacturing at a $145M+ facility in Hamilton, Ontario, while the Centre for Cell and Vector Production (CCVP) in Toronto supports Phase I and II clinical trial production across 10 ISO Class 7 clean rooms.
Product overview
CCRM operates as a catalyst for commercializing regenerative medicine technologies and cell and gene therapies. The organization offers an integrated commercialization model comprising CGT Manufacturing services, a Technology Development Incubation Program, Venture Investment, and specialized infrastructure including the Centre for Cell and Vector Production (CCVP). Through its DeepTech Bio Lab, CCRM applies quantum, AI, and robotics to life science applications. The company's CDMO subsidiary OmniaBio provides commercial-scale manufacturing capacity. Together, these offerings enable product development through translational platforms that address key bottlenecks in regenerative medicine commercialization.
Differentiator
Problem solved
Functional benefit
Brands
- DeepTech Bio Lab™: A unique workspace leveraging data and testing technologies that apply deep tech (quantum, AI, robotics) to life science applications, particularly cell and gene therapies.
- CCRM Foundation
Products and services
- CGT Manufacturing Services End-to-end cell and gene therapy manufacturing services covering process development, GMP production, technology transfer, and specialized infrastructure for advanced therapy developers, biotech, and pharma companies.
- Technology Development Incubation Program Incubation program that transforms academic regenerative medicine and cell/gene therapy discoveries into market-ready ventures by bundling IP from academic institutions, generating proof-of-concept data, and launching companies. Has produced 18 portfolio companies with 2 exits and CA$1.2B+ raised to date.
- Venture Investment Investment services that provide capital, infrastructure access, and strategic expertise to support growth of advanced therapy companies developing cell and gene therapies.
- DeepTech Bio Lab A specialized workspace leveraging data and testing technologies that apply deep tech including quantum computing, artificial intelligence, and robotics to life science applications, particularly cell and gene therapy discovery and manufacturing.
- Centre for Cell and Vector Production (CCVP) A 20,000 sq. ft. GMP-compliant facility with 10 ISO Class 7/Grade B clean rooms for producing cells and viral vectors for Phase I and II clinical trials, operated in partnership with University Health Network.
- OmniaBio CDMO Services Contract Development and Manufacturing Organization (CDMO) services provided through wholly-owned subsidiary OmniaBio Inc., delivering commercial-scale cell and gene therapy manufacturing from a $145M+ facility at McMaster Innovation Park with 100,000 sq. ft. of manufacturing space.
- Venture by Design A venture development service that supports the creation and scaling of companies operating at the interface between academia and industry in regenerative medicine and cell/gene therapy.
Quantifiable outcome
- Portfolio companies have raised >CA$1.2B to date
- +2 more outcomes
Companies that use CCRM
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
CCRM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CCRM partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered major, strategic, core, minor and regional.
- AvectasmajorAgreement with CCRM and OmniaBio to evaluate Avectas' automated, integrated and scalable cell therapy manufacturing platform. Partnership aims to improve automation, scalability and manufacturing efficiency to address key challenges limiting patient access to cell and gene therapies.
- Government of IrelandstrategicGovernment MOU between Ireland and Canada supporting establishment of CCRM Ireland and expanded life science collaboration.
- IonQcoreStrategic collaboration and investment partnership to develop advanced therapeutics using hybrid quantum and quantum-AI technologies. Focus areas include bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation for advanced therapy manufacturing. Initial projects planned for Canada and Sweden in 2026.
- AfryminorEngineering partner for CCRM Nordic's Mölndal facility development in Sweden.
- PHC Holdings CorporationmajorPartnership to advance cell and gene therapy manufacturing through development of primary T-cell expansion culture processes.
- SCTbioregionalPartnership between SCTbio and CCRM Nordic to advance cell and gene therapy development and production in Europe.
- Somite TherapeuticsmajorCollaboration to advance cell therapy flagship program through OmniaBio's manufacturing capabilities.
- Medicine by DesigncoreAlliance to bolster Canada's leading position in regenerative medicine, combining CCRM's commercialization expertise with Medicine by Design's research capabilities.
- Catamaran BiomajorPartnership with OmniaBio to advance allogeneic CAR-NK cell therapies using CCRM's manufacturing infrastructure.
- MicrofluidXminorPartnership on end-to-end bioprocessing of CAR-T cell therapies.
- MembiominorPartnership to develop single-use bioreactor to streamline viral vector production for cell and gene therapies.
- AvectasmajorExpanded collaboration between Avectas, CCRM and OmniaBio Inc. for cell therapy manufacturing platform development.
- Resolution TherapeuticsminorResearch collaboration agreement with Resolution Therapeutics.
- MedipostmajorOmniaBio and Medipost acquisition and investment deal for CARTISTEM development and commercialization.
- University Health NetworkcorePartner in building the Centre for Cell and Vector Production (CCVP) GMP facility for producing cells and viral vectors for clinical trials.
- Founding Institutional MemberscoreNetwork of founding institutional members supporting CCRM's mission and providing ongoing academic and research partnerships.
Scale indicators8 records
Recent moves9 records
Expansion highlights5 records
CCRM competitors and assessment
Company assessmentBroad incumbents
- Lonza: Global leader in contract development and manufacturing for biologics and cell & gene therapies, with significant GMP viral vector and cell therapy capacity. Directly competes with CCRM/OmniaBio for advanced therapy manufacturing contracts at a much larger scale.
- Catalent: Major CDMO with dedicated cell and gene therapy services including viral vector and plasmid manufacturing. Competes with CCRM for commercial and clinical-stage CGT manufacturing programs across North America and Europe.
- Thermo Fisher Scientific (Patheon): Pharma services division offering biologics and cell/gene therapy CDMO capabilities through Patheon and viral vector manufacturing. A broad incumbent competing with CCRM/OmniaBio on integrated development and manufacturing offerings.
- WuXi Advanced Therapies: Cell and gene therapy CDMO arm of WuXi AppTec offering viral vector, cell therapy, and plasmid manufacturing. A broad incumbent competing with CCRM globally across CGT development and manufacturing.
Direct peers
- Forge Biologics: US-based hybrid CDMO and gene therapy development company focused on AAV viral vector manufacturing and gene therapy services. Closely comparable to CCRM/OmniaBio as a specialized CGT CDMO with platform-level integration.
- Andelyn Biosciences: AAV and gene therapy CDMO spun out of Nationwide Children's Hospital with GMP viral vector manufacturing capacity. Comparable to CCRM's CCVP and OmniaBio capabilities in clinical and commercial gene therapy manufacturing.
- Viralgen Vector Core (AskBio): AAV-focused CDMO with commercial-scale viral vector manufacturing based in Spain. Directly comparable to CCRM/OmniaBio's gene therapy manufacturing capacity for clinical and commercial supply.
- AGC Biologics: Global biologics CDMO with cell and gene therapy services including viral vector and cell therapy manufacturing. Comparable in service scope and clinical/commercial focus to CCRM/OmniaBio.
Emerging players
- ElevateBio: Cell and gene therapy company combining in-house therapeutic development with BaseCamp CDMO capabilities. Comparable to CCRM in integrating incubation/venture creation with CGT manufacturing, though structured as a for-profit.
- Cellares: Emerging cell therapy manufacturing technology company developing automated, high-throughput cell therapy manufacturing platforms. Adjacent peer relevant to CCRM through the Avectas automation partnership and DeepTech Bio Lab robotics focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CCRM social profiles
Digital presenceCCRM financial estimates
Financial estimateRevenue estimate
Valuation estimate
CCRM leadership team
Management profileNumber of profiles
Profiles5 records
CCRM subsidiaries and ownership
Company hierarchySubsidiaries4 records
CCRM funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CCRM M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CCRM
What does CCRM do?
CCRM is a not-for-profit commercialization catalyst for regenerative medicine and cell/gene therapies, offering an integrated platform that bundles technology sourcing from academic labs, IP licensing, company incubation, venture investment, and GMP manufacturing services. Its wholly-owned CDMO subsidiary OmniaBio delivers commercial-scale cell and gene therapy manufacturing at a $145M+ facility in Hamilton, Ontario, while the Centre for Cell and Vector Production (CCVP) in Toronto supports Phase I and II clinical trial production across 10 ISO Class 7 clean rooms.
Is CCRM a public or private company?
CCRM is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was CCRM founded?
CCRM was founded in 2011. It employs 101 to 250 people.
Where is CCRM based?
CCRM is headquartered in Toronto, Canada, in the North America region.
How does CCRM make money?
Four revenue lines are on record. CDMO Services (OmniaBio) is the primary driver. The others are technology Incubation and Licensing, professional Services and lab Contract Services.
Who are CCRM's main competitors?
Broad incumbents on record are Lonza, Catalent, Thermo Fisher Scientific (Patheon) and WuXi Advanced Therapies. Direct peers are Forge Biologics, Andelyn Biosciences, Viralgen Vector Core (AskBio) and AGC Biologics. Emerging players are ElevateBio and Cellares.
Does CCRM have an API?
No public API is recorded for CCRM.
What industry is CCRM in?
CCRM's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing). Its NAICS code is 541714 and its SIC code is 8731.